The French Competition Authority imposes fines totalling €444 million on three laboratories for abuse of collective dominance in the market for the treatment of age-related macular degeneration (Novartis / Roche / Genentech)

KEYWORDS
Reference

French Competition Authority, Novartis / Roche / Genentech, Press Release, 9 September 2020

On 9 September 2020, the French Competition Authority (FCA) imposed fines totalling €444 million on three laboratories (Novartis, Roche and Genentech) for having abused their collective dominant position in the market for the treatment of age-related macular degeneration (AMD). The facts that led to the FCA's decision had already been investigated and sanctioned by the Italian Competition Authority (ICA) in 2014 on different grounds. It is worth briefly recalling the facts. Genentech developed two medicines: Lucentis, which was authorised by the European Commission and the European

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • White & Case (Brussels)
    Germany 17 contributions 6773 visits
  • White & Case (Brussels)
    Belgium 5 contributions 1058 visits
  • White & Case (Brussels)
    Belgium 3 contributions 406 visits

Quotation

Axel P. Schulz, Fanny Abouzeid, Joao Lacerda, The French Competition Authority imposes fines totalling €444 million on three laboratories for abuse of collective dominance in the market for the treatment of age-related macular degeneration (Novartis / Roche / Genentech), 9 September 2020, e-Competitions September 2020, Art. N° 104695

Visites 107

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues